Yongkai Li
Novartis
14 Papers
180 Citations
Yongkai Li is an academic researcher from Novartis. The author has contributed to research in topics: Adjuvant & Receptor. The author has an hindex of 7, co-authored 14 publications. Previous affiliations of Yongkai Li include Novartis Foundation & Genomics Institute of the Novartis Research Foundation.
Chat about Author
Papers
Rational design of small molecules as vaccine adjuvants
Tom Y.-H. Wu,Manmohan Singh,Miller Andrew T,Ennio De Gregorio,Francesco Doro,Ugo D'Oro,David A. G. Skibinski,M. Lamine Mbow,Simone Bufali,Ann E. Herman,Alex Cortez,Yongkai Li,Bishnu P. Nayak,Elaine Tritto,Christophe M. Filippi,Gillis R. Otten,Luis Brito,Elisabetta Monaci,Chun Li,Susanna Aprea,Sara Valentini,Samuele Calabrό,Donatello Laera,Brunella Brunelli,Elena Caproni,Padma Malyala,Rekha G. Panchal,Travis K. Warren,Sina Bavari,Derek T. O'Hagan,Michael P. Cooke,Nicholas Valiante +31 more
TL;DR: In vivo potency can be increased with little to no systemic exposure, localized innate immune activation and short in vivo residence times of SMIP-based adjuvants, and this work provides a systematic and generalizable approach to engineering small molecules for use as vaccine adjuvant.
180
Patent
Compounds and compositions as tlr activity modulators
Tom Yao-Hsiang Wu,Yongkai Li,Alex Cortez,Yefen Zou,Pranab Mishra,Xiaoyue Zhang,David A. G. Skibinski,Manmohan Singh,Nicholas Valiante +8 more
- 27 Feb 2009
TL;DR: In this article, a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7.
89
Patent
Compounds and compositions as toll-like receptor 7 agonists
Yongkai Li,Tingting Mo,Porino Va,Tom Yao-Hsiang Wu,Xiaoyue Zhang +4 more
- 29 Apr 2015
TL;DR: In this paper, the authors provided a compounds of formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.
46
Patent
Adsorption of immunopotentiators to insoluble metal salts
Manmohan Singh,David A. G. Skibinski,Tom Yao-Hsiang Wu,Yongkai Li,Alex Cortez,Xiaoyue Zhang,Yefen Zou,Timothy Z. Hoffman,Jianfeng Pan,Kathy Yue +9 more
- 01 Sep 2011
TL;DR: In this article, a modified immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption, and these modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.
23
Topical SMIP-7.7, a toll-like receptor 7 agonist, protects against genital herpes simplex virus type-2 disease in the guinea pig model of genital herpes.
David I. Bernstein,Rhonda D. Cardin,Fernando J. Bravo,Julie Earwood,Jennifer R. Clark,Yongkai Li,Pranab Mishra,Chun Li,Bishnu P. Nayak,Andrew T. Miller,Tom Y.-H. Wu,Michael P. Cooke,Nicholas Valiante +12 more
TL;DR: SMIP-7.7 improves the outcome of primary and recurrent HSV-2 disease comparable to Aldara®, but without some of the side effects associated with Aldara®.
10